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Modeling of Pharmacokinetics of Cocaine in Human
Reveals the Feasibility for Development of Enzyme
Therapies for Drugs of Abuse
Fang Zheng, Chang-Guo Zhan*
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America
Abstract
A promising strategy for drug abuse treatment is to accelerate the drug metabolism by administration of a drug-
metabolizing enzyme. The question is how effectively an enzyme can actually prevent the drug from entering brain and
producing physiological effects. In the present study, we have developed a pharmacokinetic model through a combined
use of in vitro kinetic parameters and positron emission tomography data in human to examine the effects of a cocaine-
metabolizing enzyme in plasma on the time course of cocaine in plasma and brain of human. Without an exogenous
enzyme, cocaine half-lives in both brain and plasma are almost linearly dependent on the initial cocaine concentration in
plasma. The threshold concentration of cocaine in brain required to produce physiological effects has been estimated to be
0.2260.07 mM, and the threshold area under the cocaine concentration versus time curve (AUC) value in brain (denoted by
AUC2‘) required to produce physiological effects has been estimated to be 7.962.7 mM?min. It has been demonstrated that
administration of a cocaine hydrolase/esterase (CocH/CocE) can considerably decrease the cocaine half-lives in both brain
and plasma, the peak cocaine concentration in brain, and the AUC2‘. The estimated maximum cocaine plasma
concentration which a given concentration of drug-metabolizing enzyme can effectively prevent from entering brain and
producing physiological effects can be used to guide future preclinical/clinical studies on cocaine-metabolizing enzymes.
Understanding of drug-metabolizing enzymes is key to the science of pharmacokinetics. The general insights into the
effects of a drug-metabolizing enzyme on drug kinetics in human should be valuable also in future development of enzyme
therapies for other drugs of abuse.
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Introduction
Substance abuse and addiction are a major medical and social
problem in the world [1]. Most of substances of abuse are
psychoactive drugs, such as cocaine, illicit opiates, amphetamine-
type stimulants, ecstasy-group substances, and cannabinoids. All
psychoactive compounds have the abuse potential. Psychoactive
drugs can cross the blood-brain barrier (BBB) and act primarily on
the central nervous system (CNS) to alter brain functions, resulting
in changes in perception, mood, consciousness, cognition, and
behavior [2]. The disastrous social and economic consequences of
drug abuse and addiction have made a high priority the anti-drug
medication development.
Generally speaking, solving a drug addiction problem always
needs to account for two aspects: antagonizing the stimulant effect
of the abused drug, and bringing the function of brain’s
communication system back to normal. These two aspects are
closely related to each other for an abused drug like cocaine which
binds with dopamine transporter (DAT) in the same binding
pocket as substrate dopamine. For example, cocaine addiction is
associated with cocaine-induced change in the brain’s communi-
cation system, including the rapid upregulation of DAT expression
on the cell surface. One-time use of cocaine will increase the
surface DAT expression for at least a month, as normalization of
dopaminergic function is usually an extremely slow process [3].
Due to the increase of the surface DAT expression, there are less
dopamine molecules available in the synapse for signaling, which
likely contributes to the drug seeking or craving. So, it is necessary
for therapeutic treatment of cocaine addiction to first (directly or
indirectly) block the stimulant effects of cocaine. Without the
stimulant effects of cocaine, one can have a real chance to bring
the function of brain’s communication system back to normal.
Pharmacological treatment of drug overdose and addiction can
be either pharmacodynamic or pharmacokinetic [4]. Most of
currently employed anti-addiction strategies use the classical
pharmacodynamic approach. The classical pharmacodynamic
approach aims to develop a small molecule that interacts with
one or more neuronal binding sites, with the goal of blocking or
counteracting neuropharmacological actions of the drug. Howev-
er, due to the complex interrelations of neuronal circuits, it is
difficult to accurately predict the actions of agonist/antagonist-
type of therapeutic candidates and design an agonist/antagonist
without undesirable side effects within the CNS [5]. In particular,
as cocaine binds with DAT in the same binding pocket as
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dopamine [6,7,8], it would be extremely difficult to design an
antagonist which can potently block DAT-cocaine binding without
affecting the normal function of DAT. Hence, despite decades of
effort [4,9], there is still no FDA-approved therapeutic agent
specific for cocaine. It is highly desirable to develop novel
pharmacological approaches to treatment of cocaine overdose and
addiction.
Due to the inherent difficulties in antagonizing a blocker like
cocaine in the CNS, pharmacokinetic approaches are particularly
interesting for possible treatment of cocaine overdose and
addiction. A pharmacokinetic agent aims to act directly on the
drug itself to alter its distribution or accelerate its clearance [4]. A
pharmacokinetic agent could be a protein, such as an antibody,
which binds tightly to the drug such that the drug-antibody
complex cannot cross the BBB [4]. In practice, the anti-cocaine
antibody could be provided with either active immunization
(vaccine) or passive immunity (monoclonal antibody produced in
another host). A pharmacokinetic agent could also be an
appropriately designed cocaine-metabolizing enzyme [10,11] that
not only binds with cocaine but also accelerates cocaine
metabolism and thereby freeing itself for further binding. Thus,
an enzyme molecule can be used repeatedly until all cocaine
molecules are metabolized. Clearly, a pharmacokinetic approach
(enzyme, antibody or vaccine) has a potential advantage over the
classic pharmacodynamic approach using a small-molecule
agonist/antagonist, because a pharmacokinetic agent usually does
not cross the BBB to reach the CNS. So, an appropriately
designed pharmacokinetic agent is not expected to block the
normal functions of the transporters and receptors in the CNS
[10]. Concerning the enzyme-based approach, the remaining
question is how effective a drug-metabolizing enzyme can prevent
the drug from entering brain and producing physiological effects.
Here we address this question by taking cocaine pharmacokinetics
[12,13] as a typical example.
It has been recognized as a promising anti-cocaine medication
to accelerate cocaine metabolism in plasma, producing biologically
inactive metabolites via a route similar to the primary cocaine-
metabolizing pathway in plasma, i.e. cocaine hydrolysis catalyzed
by butyrylcholinesterase (BChE), as BChE-catalyzed hydrolysis of
cocaine produces biologically inactive metabolites [9,10]. The
other possibly valuable pharmacokinetic agents capable of
accelerating cocaine metabolism that have been investigated so
far include anti-cocaine catalytic antibodies [11,14,15] and
bacterial cocaine esterase (CocE) [16,17,18]. The catalytic
antibodies, wild-type BChE, and BChE mutants discovered earlier
have a low catalytic activity against naturally occurring (2)
-cocaine [19,20,21,22,23]. However, CocE (particularly its ther-
mostable mutants) [24] and our recently designed mutants of
human BChE with a considerably improved catalytic activity
against (2)-cocaine [9,25,26,27,28,29,30,31] are promising for not
only therapeutic treatment of cocaine overdose [29,32,33], but
also possible treatment of cocaine abuse [33,34]. It has also been
demonstrated that our rationally designed mutations on human
BChE only considerably and selectively increase the catalytic
activity of the enzyme against (2)-cocaine without a significant
increase in the catalytic activities against other substrates tested
[32], including acetylcholine (which is the only natural substrate in
the body), suggesting that these BChE mutants are safe. Our
reported BChE mutants with at least ,1,000-fold improved
catalytic activity against (2)-cocaine are also known as cocaine
hydrolases (CocHs) in literature [35].
Strategy using an enzyme to treat cocaine abuse is based on the
idea that the enzyme can alter the pharmacokinetics of cocaine in
a favorable manner by rapidly metabolizing cocaine. In this way,
an enzyme agent could reduce cocaine’s entry into the brain to a
certain amount (threshold) that is too low to cause cocaine-elicited
drug seeking or toxicity etc. [9] Plenty of experimental results from
animal studies have demonstrated that an enzyme like CocH or
CocE with a high catalytic activity against (2)-cocaine is effective
to protect animals from the acute cocaine toxicity
[23,30,32,33,34,36]. In addition, our previously reported
A199S/S287G/A328W/Y332G mutant of human BChE (denot-
ed by CocH1 in this report for convenience) [28] was fused with
human serum albumin by Brimijoin et al. [36] to extend its in vivo
half-life. It has been shown that the albumin-fused CocH1 and
thermosatble CocE mutants are all capable of reducing the
stimulant effects of the self-administered cocaine and blocking
cocaine-primed reinstatement of drug-seeking [33,34,36]. For the
treatment of cocaine abuse, one would expect that a CocH or
CocE can be used to build a strong defense system through rapidly
degrading cocaine in plasma so that the cocaine molecules are
prevented from entering the brain.
Therefore, it is important to understand cocaine pharmacoki-
netics in the presence of a high-activity cocaine hydrolase. For the
purpose, we first theoretically evaluated CocH as a potential
therapeutic treatment of cocaine overdose and abuse. The
evaluation is based on the development of a two-compartment
pharmacokinetic model (representing the time-dependent concen-
trations of (2)-cocaine in plasma and in brain) with Michaelis-
Menten elimination of cocaine in plasma of human (i.e. the
endpoint user of our CocH). Pharmacokinetic modeling can be
performed to appropriately address such essential questions as:
What amount of cocaine can a given concentration of the cocaine-
metabolizing enzyme effectively prevent from entering brain and
producing physiological effects? What are the minimum require-
ments for the catalytic activity and concentration of the enzyme
used to treat a given dose of cocaine? What are the effects of the
catalytic parameters (catalytic rate constant kcat and Michaelis-
Menten constant KM) of the enzyme on the cocaine abuse
treatment? Insights obtained from the pharmacokinetic modeling
could provide a clear roadmap and baseline for future develop-
ment of an enzyme-based therapy for cocaine abuse. Such
Author Summary
In this computational study, we have examined, for the
first time, the potential effects of a drug-metabolizing
enzyme on drug pharmacokinetics in human, showing that
a high-activity drug-metabolizing enzyme can completely/
effectively prevent the drug of abuse from entering brain
to produce physiological effects. Based on this encourag-
ing insight, it is feasible to develop enzyme therapies for
drugs of abuse. Through pharmacokinetic modeling, we
have demonstrated that, without an exogenous enzyme,
the drug half-lives in both brain and plasma are almost
linearly dependent on the initial drug concentration in
plasma. This finding indicates that one may not simply say
the half-life of a drug without clearly indicating the actual
dose condition. We have also demonstrated for the first
time how a high-activity drug-metabolizing enzyme can
considerably decrease the peak concentration of drug in
brain and drug half-lives in both brain and plasma. In
addition, we have calculated the minimum (threshold)
concentration of cocaine in brain required to produce
physiological effects. The predicted threshold concentra-
tion, along with all of the general insights obtained in this
study, will provide a rational base for future design of
further experimental studies required for the enzyme
therapy development.
Pharmacokinetics of Cocaine in Human
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pharmacokinetic modeling would help to make the in vivo studies
much more efficient and, thus, help to considerably reduce the
animal sacrifice, experimental labors, and financial expenditure
for the in vivo tests with the enzyme and cocaine. In the present
study, we have developed a pharmacokinetic model by utilizing
available experimental data from the direct measurements of
cocaine in the brains and plasma of normal human volunteers
made by using positron emission tomography (PET) and tracer
doses of [11C]cocaine, i.e. N-11C-methyl-(-)-cocaine [37]. The
developed pharmacokinetic model has been used to clearly address
the fundamental questions mentioned above, for the first time,
providing valuable insights into the effects of the enzyme on the
action of cocaine.
Methods
Theoretical model
A two-compartment in vivo pharmacokinetic model (Figure 1)
with Michaelis-Menten elimination in plasma was built to describe
the cocaine concentration-time profile in the human body and
characterize the relationship between the profile and the observed
pharmacological activity of cocaine reported by Fowler et al. [37]
Assuming that all compartments are homogeneous, the model is
based on the following differential equations:
dx1(t)
dt
~{½Vmax=(KMzx1(t))zKpbx1(t)zKbpx2(t) ð1Þ
dx2(t)
dt
~
Vp
Vb
½Kpbx1(t){Kbpx2(t) ð2Þ
where x1(t) and x2(t) represent the cocaine concentrations in
plasma (compartment 1) and brain (compartment 2), respectively.
KM is the Michaelis-Menten constant of the enzyme for cocaine.
Vmax is the maximum rate of the enzymatic reaction when the
enzyme is saturated by the substrate (cocaine): Vmax;kcat?[E] in
which kcat is the catalytic rate constant and [E] is the concentration
of the enzyme in plasma. Kpb is the constant for cocaine diffusion
from plasma compartment to brain compartment, and Kbp is the
constant for cocaine diffusion from brain compartment to plasma
compartment. Vp and Vb refer to the effective volumes of
compartments 1 (plasma) and 2 (brain), respectively. Standard
Michaelis-Menten equation of BChE-catalyzed cocaine hydrolysis
was used for a couple of reasons: (1) BChE-catalyzed hydrolysis of
cocaine is the dominant cocaine-metabolizing pathway in plasma
and the other cocaine-metabolizing pathways may be neglected
[10]; (2) the products of BChE-catalyzed hydrolysis of cocaine do
not significantly inhibit BChE [38]. Further, in the presence of an
exogenous cocaine-metabolizing enzyme with a .1,000-fold
improved catalytic efficiency against cocaine, the catalytic activity
of the endogenous enzyme is negligible.
Concerning the structural identifiability [39,40,41] of the
model, there are two model outputs, denoted by y1(t) and y2(t)
for convenience, and we have y1(t)~bx1(t) and y2(t)~cx2(t) in
which b~Vp=D as discussed below. Vb, Vp, Kpb, and Kbp are
unknown parameters/variables, whereas c, Vmax, and KM are the
known constants (see below). It should be noted that Vb, Vp, Kpb,
and Kbp all must be positive values in order to be physically
meaningful. An analysis using the Taylor series expansion method
revealed that there is only one physically meaningful solution for
the values of parameters Vp, Vb, Kpb, and Kbp used in the model.
So, under the condition that Vp, Vb, Kpb, and Kbp all must be
positive values, all unknown parameters of the model associated
with Eqs.(1) and (2) are uniquely identifiable and, therefore, the
model is structurally identifiable.
Model fitting and parameter estimation
PET data were selected to fit the model as PET is superior over
other techniques, such as microdialysis, that have been used to
determine the cocaine distribution and its time course in living
subject (human). In addition, PET imaging analysis can reveal the
variation of cocaine concentration in brain starting from seconds
after cocaine is injected into a living subject. Therefore, the
theoretical model was fitted to the experimentally observed data
reported by Fowler et al. [37] These PET data were chosen based
on several reasons. First, the PET data were obtained for human
subjects, which is consistent with kcat and KM of human BChE that
we have been studying in our lab [28,29,30,31,32]. Second, the
cocaine concentrations in plasma at various time points were also
measured for the same subject(s) along with the PET measure-
ment. In addition, the time course of cocaine appearing in the
striatum of brain [37] is consistent with the time course of the
mean subjective ‘‘high’’ in human subjects reported by Cook et al.,
[42] a well-documented euphoria experienced after the intrave-
nous (i.v.) administration of cocaine.
The experimental data – uptake and clearance of the
[11C]cocaine radioactivity in the human corpus striatum over a
35-minute period after the injection of [11C]cocaine depicted in
Figure 2 of the previous report [37], and the relative concentration
of [11C]cocaine in human plasma depicted in Figure 4A of the
previous report [37] – were digitized for fitting with the results
obtained from the theoretical pharmacokinetic simulation. Al-
though the experimental data for uptake and clearance of the
[11C]cocaine radioactivity in the human cerebellum were also
available, we chose not to directly model these data in our finally
generated model because cocaine always had the highest
concentration in the striatum [37,43]. To include the uptake
and clearance of radioactivity in the human cerebellum, one more
compartment and three additional parameters would need to be
included in the pharmacokinetic model. The extra parameters
would add some additional flexibility (and also uncertainty) to the
Figure 1. A two-compartment model. The model has one
compartment representing brain (striatum) tissue, which exchanges
radiotracer with plasma compartment (volume Vp) with two diffusion
constants Kpb and Kbp. In the plasma compartment, cocaine molecules
experience an enzymatic Michaelis-Menten elimination, where KM is the
Michaelis-Menten constant and Vmax is the maximum velocity of
cocaine conversion to the metabolites.
doi:10.1371/journal.pcbi.1002610.g001
Pharmacokinetics of Cocaine in Human
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model during the calibration of the model parameters. The
difference for the distribution of (2)-cocaine in brain other than
striatum can be corrected by adjusting the volume parameter Vb
during the model fitting.
Our pharmacokinetic modeling and simulation were performed
by use of ADAPT II program [44] and a MATLAB program
developed in our own lab for numerical solution of differential
equations defined in Eqs.(1) and (2) [45,46,47]. Curves of the
cocaine concentrations versus time in both compartments gener-
ated by numerical integration were evaluated for the closest to the
observed PET data. The fitting was judged by using the root-
mean-squared error (RMSE). All points were given the equal
weight during the least-squares fitting process.
Area under the curve (AUC) analysis
The cocaine exposure in brain can be characterized by the area
under the cocaine concentration versus time curve (AUC) in brain.
For convenience, the AUC values in plasma and brain within time
t after the cocaine administration are denoted by AUC1t and
AUC2t, respectively, and can be evaluated via
AUCit~
ðt
0
xi(t)dt ð3Þ
in which i=1 and 2 that refer to plasma and brain, respectively. In
practice, the numerical integration with Eq.(3) was carried out by
using the well-known linear trapezoidal rule. AUCit=AUCi‘
when t=‘.
Results
Model parameters
We have developed a two-compartment in vivo pharmacokinetic
model. The model has compartments: one compartment repre-
sents brain (striatum) tissue with volume Vb, and the other
represents plasma with volume Vp. The compartments exchange
cocaine molecules, characterized by two diffusion constants: Kpb
(for cocaine diffusion from plasma to brain) and Kbp (for cocaine
diffusion from brain to plasma). In the plasma compartment,
cocaine molecules experience an enzymatic Michaelis-Menten
elimination, where [E] is the enzyme concentration, KM is the
Michaelis-Menten constant, and kcat is the catalytic rate constant.
The model based on Eqs.(1) and (2) involves the following
variables: kcat, KM, [E], Vb, Vp, Kpb, and Kbp. Endogenous BChE in
human plasma primarily exists in tetramer with a mass of
340 kDa. The tetramer accounts for 95% BChE; the remaining
5% exists in dimer (170 kDa) and monomer (85 kDa) [48]. All of
these protein oligomers are active forms of BChE. A monomer has
one active site. A dimer has two active sites. However, in the
tetramer structure, only two subunits have their catalytic sites
accessible to the substrate [49,50], while the catalytic sites of the
other two subunits are blocked by the neighboring subunits. Thus,
a tetramer of BChE only has two truly active sites. For this reason,
when we discuss the concentration and catalytic activity of BChE,
it is more convenient to talk about the molar concentration of the
BChE active site. So, the enzyme concentration [E] mentioned
below will always refer to the molar concentration of the BChE
active site. It has been known that for the endogenous BChE in
normal human plasma, kcat = 4.1 min
21, KM=4.5 mM based on in
vitro activity assays [21], and the enzyme concentration can be
taken as [E] = 0.035 mM (a constant) which is close to the medium
value within the reference concentration range (4.6 to 14 KU/L)
established in humans for BChE [51]. Based on these known kcat,
KM, and [E] values, the other parameters, including Vb, Vp, Kpb,
and Kbp, can be determined/optimized by fitting to the
experimental data [37] concerning x1(t) and x2(t) versus time in
plasma and brain, respectively.
Parameters Kbp and Kpb determine how fast cocaine diffuses
between brain and plasma. By definition, Vb and Vp are the
effective volumes of brain and plasma, respectively. Concerning
Vp, a typical adult has a blood volume between 4.7 and 5 L
including ,3 L plasma. It seems reasonable to assume that Vp is
about ,3 L. However, cocaine can actually exist in other parts of
the body in addition to plasma and brain. As a result, a reasonable
(effective) Vp value should be significantly larger than 3 L. Further,
for the given experimental dose of [11C]cocaine at ,11 mg [37],
the used Vp value determines the initial concentration of
[11C]cocaine (when t=0) in plasma. Hence, in principle, the Vp
value may be evaluated by using the measured x1(0) value, i.e. the
initial concentration of [11C]cocaine in plasma. However, it has
been difficult to determine x1(0) accurately in human plasma.
Reported in ref. [37] were the relative x1(t) values, or y1(t) values
with y1(0)=1 (i.e. 100%). So, Vp was regarded as an adjustable
parameter. Because x1(0)~D=Vp and b~Vp=D (in which D is
the dose of cocaine used), once Vp is known, the b and x1(0) values
are all known. For the similar reason, concerning the amount of
the overall cocaine entry to brain compartment, Vb was also
considered as an adjustable parameter which should be between
the volume of striatum alone (6.3360.44 cm3) and that of the
whole brain (1,253.8670.90 cm3) [52].
The Vb, Vp, Kpb, and Kbp values were optimized according to
three criteria. The first is the RMSE for the x1(t) values, denoted
by RMSE1; the smaller the RMSE values, the better the model.
The second is the RMSE for the x2(t) values, denoted by RMSE2;
the smaller the RMSE values, the better the fitting. In addition,
the ratio of AUC2‘ to AUC1‘ should be consistent with available
experimental observations. Through microdialysis studies on
freely-moving rats, Hedaya et al. [53,54] observed that the ratio
of cocaine AUC in brain extracellular fluid to that in plasma after
the cocaine administration was 1.2060.18 (or 1.02 to 1.38). In
light of their experimental results, the ratio of AUC2‘ to AUC1‘ is
expected to be slightly larger than 1 within the range of 1.02 to
Figure 2. Modeling of available experimental data (dots) for
the concentrations of cocaine in brain (black) and in plasma
(red) of human subject. The experimental data came from reference
[37].
doi:10.1371/journal.pcbi.1002610.g002
Pharmacokinetics of Cocaine in Human
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1.38. Based on the fitting, we obtained Vb = 0.3292 L,
Vp = 11.89 L, Kpb = 0.01898 min
21, and Kbp = 0.01780 min
21.
The fitted curves are depicted in Figure 2. The corresponding
computational and experimental values are provided as supporting
information for comparison. By using the optimized Vb, Vp, Kpb,
and Kbp values, we obtained RMSE1= 0.00010 mM with Pearson
correlation coefficient r=0.992, RMSE2= 0.000128 mM with
r=0.995, AUC1‘=0.091 mM?min, and AUC2‘=0.097 mM?-
min. The data depicted in Figure 2, the low RMSE values, and the
high Pearson correlation coefficient values all suggest that the
fitting was satisfactory.
The optimized Vb value of 0.3292 L is within the aforemen-
tioned range between the volume of striatum alone
(6.3360.44 cm3) and that of the whole brain
(1,253.8670.90 cm3) as expected. The optimized Vp value of
11.89 L is larger than the typical volume (,3 L) of the plasma, as
expected in the above discussion of the possible reasons. The
difference between the optimized Vp value and the typical plasma
volume may be also partially due to the possible errors of other
non-adjustable parameters ([E], kcat, and KM). In particular, the
used kcat and KM values were determined in vitro as mentioned
above, and the actual in vivo activity of the endogenous enzyme
(wtBChE) could deviate from the measured in vitro activity of the
same enzyme. Further, based on the optimized Kpb, Kbp, AUC1‘,
and AUC2‘ values, we have AUC2‘/AUC1‘<Kpb/Kbp =,1.1.
The result of AUC2‘/AUC1‘<Kpb/Kbp and the well-fitted curves
depicted in Figure 2 also suggest that cocaine diffusion across the
BBB was fast enough to always keep an equilibrium distribution
between brain and plasma after a few minutes. As well known, like
many other amine drugs, a cocaine molecule has two protonation
states (i.e. the protonated cocaine which is the active cocaine state
and the free base which can easily cross the BBB) coexisting in the
body via rapid protonation and deprotonation processes. Whereas
the protonated cocaine state is responsible for its biological
function, the free base state is responsible for crossing the BBB.
The two states of cocaine can quickly reach the thermodynamic
equilibrium associated with pKa = 8.6 [55]. One may expect that
the Kpb/Kbp value should be close to the ideal value 1.0 for the
diffusion process. The optimized Kpb/Kbp value of ,1.1 is slightly
larger than 1.0, which might be attributed to the implicitly used
approximation which ignores DAT binding with cocaine in the
brain. Nevertheless, the minor difference between the optimized
Kpb/Kbp value of ,1.1 and the ideal value 1.0 suggests that the
effect of the DAT binding is not dramatic. The result of AUC2‘/
AUC1‘=,1.1 is consistent with the above-mentioned range (1.02
to 1.38), which further suggests that the model is reasonable. The
reasonable model has been used to predict cocaine concentrations
in brain under various dose conditions (with [E] being a constant),
as discussed below. See supporting information for more detailed
data and discussion of the impacts of the catalytic parameters of
enzyme on the cocaine concentration in brain. [E] was considered
as a constant for all enzymes in the present study, because it was
demonstrated [56] that the constant enzyme concentration can be
reached through delivering the genes of the enzyme (correspond-
ing to the enzyme-based gene therapy). The cocaine hydrolase
gene therapy aims to produce a constant enzyme concentration in
plasma. The reported gene delivery of a BChE mutant successfully
produced the BChE mutant in rat plasma with a concentration as
high as 0.5 mM [56].
Correlation between the initial cocaine concentration in
plasma and cocaine half-life in brain
Now that the values of all parameters (i.e. kcat, KM, [E], Vb, Vp,
Kpb, and Kbp) in Eqs.(1) and (2) have been known, the model can
be used to examine whether cocaine half-life in brain is dependent
on the initial dose of cocaine in plasma, i.e. x1(0). Here, the
cocaine half-life in brain, denoted by tb1/2, is defined as the time (t)
when x2(t) is equal to a half of the peak concentration of cocaine,
i.e. the maximum x2(t) value, in brain. tb1/2 becomes longer when
x1(0) increases, which indicates the nonlinearity of cocaine
pharmacokinetics (see supporting information for the plots). A
drug with nonlinear pharmacokinetics has a half-life that varies as
a function of the (initial) cocaine plasma concentration. With only
wild-type BChE (wtBChE), tb1/2 increases with x1(0) almost
linearly. When tb1/2 is in min and x1(0) is in mM, the linear
variation of cocaine half-life in brain can be described by an
approximate equation:
tb1=2~3:4627|x1 0ð Þz21:932 ð4Þ
with a high correlation coefficient (r) of 0.9998. Accordingly, the
linear variation of cocaine half-life in plasma can be represented as
tp1=2~3:3845|x1 0ð Þz21:200 ð5Þ
with r=1.0000. Eqs.(4) and (5) were obtained from fitting a
straight line model to the cocaine half-lives predicted actually from
the pharmacokinetic model. Equations (4) and (5) clearly reveal
that the cocaine half-lives in both plasma and brain are linearly
dependent on the actual cocaine dose which determines the initial
cocaine concentration in plasma, i.e. the x1(0) value in the
equations. The approximate linear correction reflected in Eqs.(4)
and (5) can be attributed to the saturation of the endogenous
cocaine-metabolizing enzyme (wtBChE) when the cocaine con-
centration is high compared to the rather low concentration
(0.035 mM) of wtBChE with KM=4.5 mM. When the enzyme is
saturated, further increasing the initial cocaine concentration can
no longer increase the overall velocity of the cocaine metabolism
and, therefore, the time required to metabolize a half amount of
cocaine will be linearly proportional to the initial concentration of
cocaine. Certainly, when the initial cocaine concentration is very
low compared to the corresponding concentration of the
endogenous enzyme, the actual correlation between the cocaine
half-life and the initial cocaine concentration will significantly
deviate from the ideal linear correction.
We note that, in theory, the half-life of a drug in nonlinear
kinetics is not a constant because the rate of elimination is
dependent on the drug concentration. Nevertheless, in vivo half-
lives of cocaine have been reported in literature and, thus, Eqs.(4)
and (5) may be used conveniently to better understand and predict
the experimental half-lives. In addition, under the same cocaine
dose condition, the relative half-lives of cocaine reflect the relative
in vivo potency of various cocaine-metabolizing enzymes. Notably,
the linear dependence of cocaine half-life in plasma is qualitatively
consistent with the experimental observation reported by Barntt et
al. over the cocaine dose range of 1–3 mg/kg when cocaine was
given to human subjects intravenously [57].
In the presence of CocH3 (i.e. A199S/F227A/S287G/A328W/
Y332G mutant of human BChE) with a KM=3.1 mM and
kcat = 5,700 min
21) [30], when x1(0),200 mM, cocaine half-life,
tb1/2, in brain is almost a constant of 1.1 min; only in the case of
extremely high cocaine concentration when x1(0).200 mM, tb1/2
increases slightly; see supporting information for the plots of tb1/2
versus x1(0). The enzyme-caused remarkable decrease in tb1/2
clearly suggests that CocH3 is an excellent agent for protecting a
living subject from the cocaine toxicity, which has been verified by
the fact that a small dose (0.01 mg/mouse, i.v.) of CocH3 can fully
Pharmacokinetics of Cocaine in Human
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protect the mice from the acute toxicity of a lethal dose of cocaine
(180 mg/kg, i.p.) [30,32]. The encouraging results with CocH3
reveal that increasing the catalytic activity of the cocaine-
metabolizing enzyme in plasma indeed can decrease the half-life
(tb1/2) of cocaine in brain.
Evaluation of available high-activity cocaine-
metabolizing enzymes for their effects on the cocaine
concentration in brain
The calibrated model has been employed to evaluate currently
available high-activity cocaine-metabolizing enzymes, including
CocE, CocH1 (i.e. A199S/S287G/A328W/Y332G mutant of
human BChE), CocH2 (i.e. A328W/A199S/F227A/E441D/
S287G mutant of human BChE), and CocH3 (i.e. A199S/
F227A/S287G/A328W/Y332G mutant of human BChE), for
their effects on the cocaine concentration in brain with a given
initial cocaine concentration in plasma. According to the previous
reports [17,18], the catalytic efficiency (kcat/KM) of wild-type
bacterial CocE (kcat = 468 min
21 and KM=0.64 mM) against (2)-
cocaine is ,800 fold higher than that of wild-type human BChE.
CocH1 (kcat = 3,060 min
21 and KM=3.1 mM) [29,31,32], CocH2
(kcat = 1,730 min
21 and KM=1.1 mM) [29,31,32], and CocH3
(kcat = 5,700 min
21 and KM=3.1 mM) [29,30,31,32] has a
,1,080-, ,1,730-, and ,2,020-fold improved catalytic efficiency,
respectively, compared to wild-type human BChE against (2)-
cocaine.
With each of these high-activity enzymes, we examined their
effects under various concentrations. Two enzyme concentrations
were examined: 0.035 and 0.5 mM. We are interested in
0.035 mM, because it is the physiologic concentration of the
endogenous BChE (wtBChE) as discussed above. We are also
interested in 0.5 mM, because it has been known that a gene
transfer produced a BChE mutant with a constant concentration
of 0.5 mM in plasma for a few months [56,58]. According to
previous studies [23,59], the most interesting cocaine doses
relevant to the addiction and overdose are associated with plasma
cocaine concentrations between 0.32 mM and 200 mM. 1–5 mM
cocaine in plasma are regarded as the commonly abused doses to
be used to get the reward effects of cocaine [60], whereas 3–
200 mM cocaine in plasma would be considered as an overdose
with the higher end being lethal [23]. Thus, we examined
x1(0)=0 to 200 mM. Numerical results of the cocaine peak
concentration, the peak time, tb1/2, and the area under curve in
human brain (AUC2‘) obtained for four exogenous enzymes with
five representative x1(0) values (1, 5, 50, 100, and 200 mM)
corresponding to [E] = 0.035 mM are summarized in Table 1. The
corresponding results corresponding to [E]= 0.5 mM are provided
in supporting information. Depicted in Figure 3 are the plots of the
peak concentration of cocaine in brain versus x1(0) for the four
enzymes with [E] = 0.035 or 0.5 mM in plasma.
A survey of the data in Table 1 reveals that the use of a high-
activity enzyme (CocH or CocE) and/or the increase of the
enzyme concentration all can decrease AUC2‘, tb1/2, peak
cocaine concentration, and peak time in brain. Because AUC2‘
and cocaine peak concentration in brain are the primary
determinants of the overall cocaine reward/stimulation effects in
brain, CocHs and CocE all can considerably decrease the overall
cocaine reward/stimulation effects in brain.
Threshold concentration of cocaine in brain to produce
physiological effects
For development of a CocH-based therapy for cocaine abuse, it
is essential to know whether a cocaine-metabolizing enzyme can
effectively prevent cocaine from entering brain and producing
physiological effects. When the cocaine concentration in brain has
never reached a ‘‘threshold’’ value in the presence of a CocH in
plasma, one may consider that the CocH has effectively prevented
cocaine from entering brain. Further, the threshold concentration
of cocaine in brain is related to the degree of the dopamine
transporter (DAT) occupancy by cocaine. Volkow and Fowler et al.
demonstrated that, for humans, ‘‘at least 47% of the transporters
had to be blocked for subjects to perceive cocaine’s effects’’ and
that 0.1 mg/kg cocaine (i.v.) producing 97625 ng/ml
(,0.32 mM) cocaine in plasma (the peak concentration) blocked
47% of the transporters [59]. In comparison, 0.05 mg/kg cocaine
(i.v.) blocked only 41% of the transporters and, thus, had no
measurable effects [59]. These experimental data for human
subjects in combination with our pharmacokinetic modeling have
provided an opportunity to estimate the threshold concentration of
cocaine in brain required to produce measurable physiological
effects.
With only the endogenous BChE at the normal concentration
(0.035 mM) in human plasma, when x1(0)=0.32 mM (associated
with the 0.1 mg/kg cocaine administered i.v.), the peak concen-
tration of cocaine in brain is calculated to be 0.29 mM and
AUC2‘=10.5 mM?min. For comparison, when x1(0)=0.16 mM
(associated with the 0.05 mg/kg cocaine administered i.v.), the
peak concentration of cocaine in brain is calculated to be 0.14 mM
and AUC2‘=5.2 mM?min. Based on these results, one can
estimate that the threshold concentration of cocaine in brain to
produce measurable physiological effects should be between 0.14
and 0.29 mM (or 0.2260.07 mM), and that the threshold AUC2‘
value of cocaine in brain to produce measurable physiological
effects should be between 5.2 and 10.5 mM?min (or
7.962.7 mM?min).
According to the estimated threshold brain cocaine concentra-
tion of ,0.22 mM, the pharmacokinetic modeling can be
performed to predict/estimate how much cocaine a given
concentration of cocaine-metabolizing enzyme can effectively
prevent from entering brain and producing physiological effects
(see Table 2 for the predictions/estimates). For example, in the
presence of 0.035 mM CocH3, the peak brain cocaine concentra-
tion corresponding to x1(0)=8 mM is predicted to be lower than
,0.22 mM. Hence, we may say that 0.035 mM CocH3 can
effectively prevent up to ,8 mM cocaine in plasma from entering
brain and producing physiological effects. 0.5 mM CocH3 can
effectively prevent up to ,40 mM cocaine in plasma from entering
brain and producing physiological effects.
As seen in Table 2, the theoretical predictions based on the
threshold AUC2‘ value are significantly different from the
corresponding predictions based on the threshold peak cocaine
concentration in brain. For example, according to the estimated
threshold AUC2‘ value of ,7.9 mM?min and the pharmacoki-
netic modeling, one may also predict/estimate that 0.035 mM
CocH3 can effectively prevent up to ,50 mM cocaine in plasma
from entering brain and producing physiological effects, and
0.5 mM CocH3 can effectively prevent up to ,200 mM cocaine in
plasma from entering brain and producing physiological effects. It
is reasonable to expect that the above predictions based on the
threshold peak brain cocaine concentration of ,0.22 mM provide
the lower limits, whereas the corresponding predictions based on
the threshold AUC2‘ value of,7.9 mM?min give the upper limits.
Comparison between the catalytic activities of CocH3
against (2)-cocaine and native BChE against (+)-cocaine
CocH3 represents a milestone because the catalytic activity of
CocH3 against (2)-cocaine (kcat = 5,700 min-1 and KM=3.1 mM)
Pharmacokinetics of Cocaine in Human
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Figure 3. Plots for the cocaine peak concentration (mM) in brain versus the initial concentration (mM) of cocaine in plasma in the
presence of a cocaine-metabolizing enzyme (0.035 or 0.5 mM).
doi:10.1371/journal.pcbi.1002610.g003
Table 1. Lookup table for the predicted cocaine peak concentration, the peak time (Ptime in min), tb1/2 (in min), and the area
under curve (AUC2‘ in human brain for a given initial concentration of cocaine with CocE or CocH or endogenous wtBChE in
plasma ([E] = 0.035 mM).
COC wtBChE CocE CocH1 CocH2 CocH3
(mM) (KM=4.5, kcat=4.1) (KM=0.64, kcat=468) (KM=3.1, kcat=3060) (KM=1.1, kcat=1730) (KM=3.1, kcat=5700)
Peak AUC2‘
Peak AUC2‘
Peak AUC2‘
Peak AUC2‘
Peak AUC2‘
(Ptime) (Ptime) (Ptime) (Ptime) (Ptime)
[tb1/2] [tb1/2] [tb1/2] [tb1/2] [tb1/2]
1 0.908 35.101 0.043 0.074 0.021 0.036 0.017 0.028 0.012 0.019
(5.101) (0.187) (0.122) (0.091) (0.075)
[27.006] [1.140] [1.088] [1.119] [1.096]
5 4.738 257.458 0.547 1.019 0.164 0.279 0.189 0.317 0.091 0.150
(5.833) (0.372) (0.147) (0.140) (0.088)
[39.863] [1.110] [1.102] [1.109] [1.083]
50 50.649 10694.160 23.636 81.804 7.204 13.917 10.732 22.789 4.239 7.488
(8.401) (1.677) (0.471) (0.683) (0.264)
[193.631] [1.868] [1.128] [1.206] [1.102]
100 102.245 39431.860 62.272 321.378 23.679 52.378 33.898 88.718 14.701 28.224
(9.337) (2.455) (0.782) (1.135) (0.471)
[366.658] [3.190] [1.206] [1.362] [1.128]
200 205.639 151038.500 150.715 1274.122 73.174 202.176 97.659 348.698 49.046 109.120
(10.380) (3.350) (1.249) (1.768) (0.782)
[715.647] [5.953] [1.440] [1.945] [1.206]
The KM values are given in mM, the kcat values are given in min
21, and the AUC2‘ values are given in mM?min.
doi:10.1371/journal.pcbi.1002610.t001
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is comparable to that of wtBChE against (+)-cocaine. An early
study reported by Sun et al. [61] determined the catalytic activities
of wild-type BChE against both (+)- and (2)-cocaine at the same
time. They determined that kcat = 6,423624 min
21 and
KM=8.560.5 mM for wild-type BChE against (+)-cocaine,
whereas kcat = 3.960.8 min
21 and KM=9.060.3 mM for wild-
type BChE against (2)-cocaine. In more recent reports on BChE
with (2)-cocaine [21], the catalytic activity of wild-type BChE
against (2)-cocaine was characterized more accurately, with
kcat = 4.1 min
21 and KM=4.5 mM. Apparently, the earlier study
[61] systematically overestimated the KM values for wild-type
BChE against both (+)- and (2)-cocaine. To verify this possibility,
we have also characterized the catalytic activities of wild-type
BChE against (+)- and (2)-cocaine at the same time, indicating
that KM=4.7 mM for wild-type BChE against (+)-cocaine while
KM=4.5 for wild-type BChE against (2)-cocaine (Yang and Zhan,
unpublished results); there was no significant difference between
our determined kcat values and previously reported kcat values. So,
the best estimate is that kcat =,6,423 min21 and KM=,4.7 mM
for wild-type BChE against (+)-cocaine, which is very close to the
catalytic activity (kcat = 5,700 min
21 and KM=3.1 mM) deter-
mined for CocH3 against (2)-cocaine. Due to the similar catalytic
activities of CocH3 against (2)-cocaine and wild-type BChE
against (+)-cocaine, the time course of (2)-cocaine concentration
in brain associated with 0.035 mM CocH3 in plasma should be
comparable to the corresponding time course of (+)-cocaine
concentration in brain associated with the normal 0.035 mM
native BChE in plasma (without an exogenous enzyme), with the
same x1(0) value (corresponding to ,11 mg) for both (+)- and (2)-
cocaine. In fact, the PET data for both [11C](+)- and [11C](2)-
cocaine in baboon (without an exogenous enzyme) were deter-
mined under the same experimental conditions by Gatley et. al., as
shown in Figure 4 (lower panel) [62]. For a qualitative comparison
between the pharmacokinetic modeling for human and the PET
data for baboon, the same pharmacokinetic model developed in
this study was employed to predict the corresponding time course
of (2)-cocaine concentration in human brain associated with
0.035 mM CocH3 in human plasma. The predicted time courses
of (2)-cocaine concentrations in human brain with and without
0.035 mM CocH3 are depicted in Figure 4 (upper panel) in
comparison with the PET data for the time courses of (2)- and (+)-
cocaine concentrations in baboon brain without an exogenous
enzyme. As seen in Figure 4, the predicted time course of (2)-
cocaine concentration in human brain associated with 0.035 mM
CocH3 is indeed very similar to the experimental time course
(PET data) of (+)-cocaine concentration in baboon brain, while the
predicted time course of (2)-cocaine concentration in human
brain without CocH3 agrees with the experimental time course
(PET data) of (2)-cocaine concentration in baboon brain. The
qualitative agreement between the computational and experimen-
tal data depicted in Figure 4 further supports that the model
developed in this study is reasonable, giving us additional
confidence in the above theoretical evaluations based on the
model concerning the perspective of future development of
cocaine hydrolase as a therapeutic treatment of cocaine overdose
and addiction.
Discussion
A pharmacokinetic model has been developed to examine the
effects of a cocaine-metabolizing enzyme in plasma on the time
course of cocaine in plasma and brain of human. The developed
pharmacokinetic model has been validated through comparison
with available PET data for both (2)- and (+)-cocaine. The
modeling has revealed various essentially important, novel insights
into cocaine pharmacokinetics in human with and without the
Table 2. The maximum cocaine plasma concentration, i.e. the
x1(0) value (mM), which a given concentration ([E] = 0.035 or
0.5 mM) of cocaine-metabolizing enzyme (CocE, CocH1,
CocH2, or CocH3) can effectively prevent from entering brain
and producing physiological effects.
[E] Criterion CocE CocH1 CocH2 CocH3
0.035 mM Threshold peaka 2 6 5 8
Threshold AUC2‘
b 15 35 28 50
0.5 mM Threshold peaka 11 28 22 40
Threshold AUC2‘
b 55 145 110 200
aThe criterion used is the threshold peak cocaine concentration of ,0.22 mM in
brain.
bThe criterion used is the threshold AUC2‘ value of ,7.9 mM?min in brain.
doi:10.1371/journal.pcbi.1002610.t002
Figure 4. Comparison between the (+)-cocaine hydrolysis by
wide-type BChE and the (2)-cocaine hydrolysis by CocH3.
Upper panel: modeled (2)-cocaine concentration in the brain of human
subject with the presence of wild-type BChE or CocH3 in plasma. Lower
panel: reported (2)- and (+)-cocaine concentrations in baboon brain
(striatum) with the presence of wild-type BChE in plasma; the data from
reference [62].
doi:10.1371/journal.pcbi.1002610.g004
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presence of an exogenous cocaine-metabolizing enzyme in plasma,
including the remarkable differences in the cocaine half-lives and
the threshold cocaine concentration or AUC2‘ in brain required
to produce physiological effects. It should be pointed out that the
current pharmacokinetic model is based on the available PET data
in human with only the endogenous enzyme (wtBChE). As it has
been well known, there is a significant difference between human
and animals in the cocaine pharmacokinetics [37]. It would be
extremely difficult to carry out the PET experiments with a
therapeutic enzyme candidate and cocaine in human to measure
the effects of an exogenous cocaine-metabolizing enzyme on
cocaine pharmacokinetics in human. To do such type of PET
experiments in human, one must first obtain FDA’s approval for
using the therapeutic enzyme candidate in human. To file a
reasonable Investigational New Drug (IND) application with FDA,
one must have compelling reasons concerning why the therapeutic
enzyme candidate should work for human. Even if with the FDA’s
IND approval, one still would have to rationally determine an
appropriate, effective concentration of the enzyme for the actual
tests in human, because one cannot test an enzyme in human for
too many times. So, this pharmacokinetic modeling in human, the
endpoint users of our potential anti-cocaine medication, is a
crucial step of our enzyme-based therapy development for cocaine
abuse. The general insights into the effects of a drug-metabolizing
enzyme on drug pharmacokinetics in human should also be
valuable for future development of an enzyme therapy for any
drug of abuse. The general methodology of the pharmacokinetic
modeling may be used to develop valuable pharmacokinetic
models for evaluating the effectiveness of metabolic enzymes in
detoxifying other drugs.
Supporting Information
Text S1 Supplementary material available including (1) analysis
of the structural identifiability of the model; (2) detailed data for
the impacts of the catalytic parameters of enzyme on cocaine
concentration in brain; (3) additional information about the
evaluation of available high-activity cocaine-metabolizing enzymes
for their effects on the cocaine concentration in brain.
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